BR112015012506A2 - tratamento de transtornos do espectro do autismo usando ácido glicil-l-2-metilprolil-l-glutâmico - Google Patents

tratamento de transtornos do espectro do autismo usando ácido glicil-l-2-metilprolil-l-glutâmico

Info

Publication number
BR112015012506A2
BR112015012506A2 BR112015012506A BR112015012506A BR112015012506A2 BR 112015012506 A2 BR112015012506 A2 BR 112015012506A2 BR 112015012506 A BR112015012506 A BR 112015012506A BR 112015012506 A BR112015012506 A BR 112015012506A BR 112015012506 A2 BR112015012506 A2 BR 112015012506A2
Authority
BR
Brazil
Prior art keywords
spectrum disorders
autism spectrum
treatment
water
glycyl
Prior art date
Application number
BR112015012506A
Other languages
English (en)
Inventor
Irwin Glass Lawrence
Fredrick Snape Michael
John Bickerdike Michael
Perez De Cogram Patricia
Original Assignee
Neuren Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Ltd filed Critical Neuren Pharmaceuticals Ltd
Publication of BR112015012506A2 publication Critical patent/BR112015012506A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo “tratamento de transtornos do espectro do autismo usando ácido glicil-l-2-metilprolil-l-glutâmico” esta invenção fornece compostos, composições e métodos para tratar transtornos do espectro do autismo (asd) usando ácido glicil-2-metiiprolil-glutâmico (g-2-mepe) e análogos do mesmo. os transtornos do espectro do autismo incluem autismo, transtorno autístico, síndrome de asperger, transtorno desintegrativo da infância, transtorno invasivo do desenvolvimento – sem outra especificação (pdd-nos), síndrome do x frágil e síndrome de rett. as composições contendo os compostos incluem formulações solúveis em água, micro-emulsões água-em-óleo, emulsões grossas água-em-óleo, cristais líquidos água-em-óleo, nanocápsulas, tabletes e géis oralmente administrados. os compostos e composições desta invenção podem ser administrados intravenosamente, intraventricularmente, parenteralmente ou oralmente e podem ser eficazes no tratamento de neurodegeneração, promoção de função neurológica, tratamento de atividade convulsiva e outros sintomas de asd e podem prolongar a vida em animais, incluindo seres humanos que apresentam transtornos do espectro do autismo.
BR112015012506A 2012-11-28 2013-11-26 tratamento de transtornos do espectro do autismo usando ácido glicil-l-2-metilprolil-l-glutâmico BR112015012506A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730829P 2012-11-28 2012-11-28
PCT/US2013/072049 WO2014085480A1 (en) 2012-11-28 2013-11-26 Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid

Publications (1)

Publication Number Publication Date
BR112015012506A2 true BR112015012506A2 (pt) 2017-07-11

Family

ID=50828422

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015012506A BR112015012506A2 (pt) 2012-11-28 2013-11-26 tratamento de transtornos do espectro do autismo usando ácido glicil-l-2-metilprolil-l-glutâmico

Country Status (6)

Country Link
EP (1) EP2928300A4 (pt)
JP (1) JP2016506380A (pt)
AU (1) AU2013352294A1 (pt)
BR (1) BR112015012506A2 (pt)
CA (1) CA2929286A1 (pt)
WO (1) WO2014085480A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10254785B2 (en) 2014-06-30 2019-04-09 Cerora, Inc. System and methods for the synchronization of a non-real time operating system PC to a remote real-time data collecting microcontroller
CA3109137A1 (en) * 2018-08-10 2020-02-13 New York Univeristy Use of igf-2 receptor agonist ligands for treatment of angelman syndrome and autism

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637567B2 (en) * 2001-05-24 2014-01-28 Neuren Pharmaceuticals Ltd. Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid
WO2006127702A2 (en) * 2005-05-23 2006-11-30 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
EP1401808B1 (en) * 2001-05-24 2009-07-08 Neuren Pharmaceuticals Limited Gpe analogs and peptidomimetics
AU2005286943A1 (en) * 2004-09-20 2006-03-30 Mount Sinai School Of Medicine Use of memantine (NAMENDA) to treat autism, compulsivity, and impulsivity
WO2007106555A2 (en) * 2006-03-14 2007-09-20 Neuren Pharmaceuticals Limited Oral formulations of glycyl-2-methylprolyl-glutamate
HUE032743T2 (en) * 2006-11-22 2017-10-30 Clinical Res Ass Llc A method for treating Down syndrome, fragilis X syndrome and autism
US7994127B2 (en) * 2007-06-08 2011-08-09 Massachusetts Institute Of Technology Treatment of rett syndrome
WO2011146109A2 (en) * 2010-05-17 2011-11-24 Mount Sinai School Of Medicine Methods and assays for treating subjects with shank3 deletion, mutation or reduced expression
US9708366B2 (en) * 2011-01-27 2017-07-18 Neuren Pharmaceuticals Ltd. Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate

Also Published As

Publication number Publication date
EP2928300A1 (en) 2015-10-14
JP2016506380A (ja) 2016-03-03
EP2928300A4 (en) 2016-07-13
AU2013352294A1 (en) 2015-07-09
CA2929286A1 (en) 2014-06-05
WO2014085480A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
EA201500923A1 (ru) Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
EA201491592A1 (ru) Соединения индолов и индазолов, активирующие ampk
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
CY1119455T1 (el) Θεραπεια διαταραχων του αυτιστικου φασματος με τη χρηση γλυκυλ-l-2-μεθυλοπρολυλ-l-γλουταμινικου οξεος
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
BR112015028452A2 (pt) agonistas do receptor somastatina subtipo 4 (sstr4)
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
BR112013032720A2 (pt) "derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados"
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
BR112015022462A8 (pt) inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores
BR112014003963A2 (pt) compostos e composições como inibidores de quinase c-kit
BR112014018199A8 (pt) inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação
EA201400161A1 (ru) Замещенные гетероароматические пиразолсодержащие карбоксамидные и мочевинные производные в качестве лигандов ваниллоидных рецепторов
EA201400392A1 (ru) ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb
EA201491606A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
CY1118966T1 (el) Νεες συνθεσεις για την προληψη και/ή την θεραπεια εκφυλιστικων διαταραχων του κεντρικου νευρικου συστηματος
MX2009004798A (es) Tratamiento de los trastornos generalizados del desarrollo.
PH12014501937A1 (en) Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
EA200900330A1 (ru) Аналоги 2-феноксипиримидинона
BR112015028516A2 (pt) tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina
BR112015012506A2 (pt) tratamento de transtornos do espectro do autismo usando ácido glicil-l-2-metilprolil-l-glutâmico
BR112013024909A2 (pt) composto, composição farmacêutica, método para o tratamento, prevenção ou melhoria de um ou mais sintomas de desordem, doença, ou condição mediada por pi3k, e método para modular a atividade enzimática de pi3k
BR112014018106A2 (pt) composto, uso de um composto, e, método para tratar uma doença fibrótica
SV2006002192A (es) Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y analogos relacionados como inhibidores de la caseina cinasa ie

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL